High-dose cis-diamminedichloro-platinum therapy in patients with advanced breast cancer: pharmacokinetics, toxicity, and therapeutic efficacy
- PMID: 7190082
High-dose cis-diamminedichloro-platinum therapy in patients with advanced breast cancer: pharmacokinetics, toxicity, and therapeutic efficacy
Abstract
Seventeen patients with advanced breast cancer were treated with cis-diamminedichloroplatinum (DDP) 100 mg per m2 every 21--28 days. Hydration and mannitol or furosemide diuresis was given. Responses were seen in two patients (one complete, one objective) with soft-tissue metastases. There was no difference in peak plasma platinum concentration (3.91 micrograms/ml +/- 1.41 micrograms/ml), terminal plasma half-life (116--288 hours), peak concentration of unbound platinum (0.7 micrograms/ml), or 24-hour urinary platinum excretion (6.7--17.2% of administered dose) between the objective responder and the nonresponders. Toxicities included severe nausea and vomiting, renal insufficiency, high-frequency hearing loss, and peripheral neuropathies. Hematologic toxicity was mild in most patients. DDP has limited activity when used as a single agent in this dose and schedule in patients with metastatic breast cancer.
Similar articles
-
High-dose cisplatin therapy using mannitol versus furosemide diuresis: comparative pharmacokinetics and toxicity.Cancer Treat Rep. 1981 Jan-Feb;65(1-2):73-8. Cancer Treat Rep. 1981. PMID: 6784924 Clinical Trial.
-
A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.Cancer J Sci Am. 1997 Sep-Oct;3(5):297-302. Cancer J Sci Am. 1997. PMID: 9327154
-
Pharmacokinetics of cis-diamminedichloroplatinum (II) given as low-dose and high-dose infusions.J Surg Oncol. 1996 Jun;62(2):135-8. doi: 10.1002/(SICI)1096-9098(199606)62:2<135::AID-JSO10>3.0.CO;2-7. J Surg Oncol. 1996. PMID: 8649040
-
Clinical pharmacology and pharmacokinetics of cis-platinum and analogs.Cancer Treat Rep. 1981;65 Suppl 3:97-105. Cancer Treat Rep. 1981. PMID: 7049371 Review.
-
Ixabepilone: a novel microtubule inhibitor for the treatment of locally advanced or metastatic breast cancer.Clin Ther. 2008 Sep;30(9):1590-617. doi: 10.1016/j.clinthera.2008.09.015. Clin Ther. 2008. PMID: 18840366 Review.
Cited by
-
Photochemical internalization-mediated delivery of chemotherapeutic agents in human breast tumor cell lines.J Environ Pathol Toxicol Oncol. 2012;31(1):49-59. doi: 10.1615/jenvironpatholtoxicoloncol.v31.i1.60. J Environ Pathol Toxicol Oncol. 2012. PMID: 22591284 Free PMC article.
-
Clinical trial of iproplatin (cis-dichloro-trans-dihydroxy-bis-isopropylamine platinum IV, CHIP) in patients with advanced breast cancer.Invest New Drugs. 1988 Jun;6(2):87-91. doi: 10.1007/BF00195365. Invest New Drugs. 1988. PMID: 3049433 Clinical Trial.
-
Cisplatin and 5-fluorouracil in refractory breast cancer patients: a phase II study.Breast Cancer Res Treat. 1988 Jul;11(3):269-71. doi: 10.1007/BF01807286. Breast Cancer Res Treat. 1988. PMID: 3167233
-
Prospective Evaluation of a Circulating Tumor Cell Sensitivity Profile to Predict Response to Cisplatin Chemotherapy in Metastatic Breast Cancer Patients.Front Oncol. 2021 Jun 25;11:697572. doi: 10.3389/fonc.2021.697572. eCollection 2021. Front Oncol. 2021. PMID: 34249756 Free PMC article.
-
Triple-negative breast cancer: role of specific chemotherapy agents.Cancer J. 2010 Jan-Feb;16(1):53-61. doi: 10.1097/PPO.0b013e3181d24ff7. Cancer J. 2010. PMID: 20164691 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical